Table 1. Patient Demographics.

IQR (Interquartile Range). N/A = Not applicable.

	Discovery Set 1	%	Discovery Set 2	%	Blinded Multi-Institution Validation Cohort	%
Total	35		48		74
Disease Group Age median, IQR	50 (43-64)		59.5 (50-68.5)		56 (46-66.5)
Healthy Group Age median, IQR	31.5 (26-52.75)		26.5 (24-29.75)		55.5 (48.5-63.3)
Non-Tumor Group Age median, IQR	N/A		N/A		66 (62-67)
Sex
Male	16	45.7	25	52.1	46	62.2
Female	19	54.3	23	47.9	28	37.8
Race, n (%)
White	31	88.6	43	89.6	65	87.8
Asian	1	2.9	2	4.2	3	4.1
Black	0	0.0	0	0.0	3	4.1
Other	2	5.7	1	2.1	0	0.0
Unavailable	1	2.9	2	4.2	3	4.1
Ethnicity, n (%)
Hispanic	1	2.9	2	4.2	0	0.0
Non-Hispanic	30	85.7	40	83.3	55	74.3
Unavailable	4	11.4	6	12.5	19	25.7
WHO Grade, n (%)
II	3	8.6	2	4.2	2	2.7
III	3	8.6	4	8.3	10	13.5
IV	16	45.7	32	66.7	33	44.6
N/A	13	37.1	10	20.8	29	39.2
Disease Status
Newly Diagnosed	21	60.0	30	62.5	39	52.7
Recurrent	4	11.4	8	16.7	18	24.3
N/A					17	23.0
Medications, n (%)
anticonvulsants (levetriacetam, clonazepam, lacosomide, carbamazepine, lamotrigine)	16	45.7	13	27.1	30	40.5
steroids (dexamethasone)	7	20.0	10	20.8	18	24.3
blood thinner (aspirin, coumadin)	3	8.6	4	8.3	9	12.2
prior radiation therapy	1	2.9	5	10.4	2	2.7
prior chemotherapy	2	5.7	8	16.7	4	5.4
clinical trial participant	1	2.9	1	2.1	6	8.1